New drug duo tested in fight against advanced cervical cancer
NCT ID NCT06238635
Summary
This study is testing whether a combination of two immunotherapy drugs, dostarlimab and cobolimab, can help control advanced cervical cancer that has spread or come back. It will involve about 66 adults whose cancer has progressed after standard platinum-based chemotherapy. The main goal is to see how many participants' tumors shrink or disappear in response to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.